FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS One / In vitro assessment of triterpenoids NVX-207 and betulinyl-b...
PloS one2020; 15(11); e0241448; doi: 10.1371/journal.pone.0241448

In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer.

Abstract: Equine sarcoid (ES) is the most prevalent skin tumor in equids worldwide. Additionally, aging grey horses frequently suffer from equine malignant melanoma (EMM). Current local therapies targeting these skin tumors remain challenging. Therefore, more feasible topical treatment options should be considered. In order to develop a topical therapy against ES and EMM, betulinyl-bis-sulfamate and NVX-207, derivatives of the naturally occurring betulin and betulinic acid, respectively, were evaluated for their antiproliferative (crystal violet staining assay), cytotoxic (MTS assay) and apoptotic (AnnexinV staining, cell cycle investigations) effects on primary ES cells, EMM cells and equine dermal fibroblasts in vitro. The more potent derivative was assessed for its in vitro penetration and permeation on isolated equine skin within 30 min and 24 h using Franz-type diffusion cells and HPLC analysis. Betulinyl-bis-sulfamate and NVX-207 inhibited the proliferation and metabolism in ES cells, EMM cells and fibroblasts significantly (p < 0.001) in a time- and dose-dependent manner. NVX-207 had superior anticancer effects compared to betulinyl-bis-sulfamate. Both compounds led to the externalization of phosphatidylserines on the cell membrane and DNA fragmentation, demonstrating that the effective mode of action was apoptosis. After 48 h of treatment with NVX-207, the number of necrotic cells was less than 2% in all cell types. Detected amounts of NVX-207 in the different skin layers exceeded the half-maximal inhibitory concentrations calculated by far. Even though data obtained in vitro are auspicious, the results are not unconditionally applicable to the clinical situation. Consequently, in vivo studies are required to address the antitumoral effects of topically applied NVX-207 in ES and EMM patients.
Get Full Text
Publication Date: 2020-11-05 PubMed ID: 33151949PubMed Central: PMC7643960DOI: 10.1371/journal.pone.0241448Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research evaluates two triterpenoids, NVX-207 and betulinyl-bis-sulfamate, as potential topical treatments for the most common skin tumors in horses: equine sarcoid and equine malignant melanoma. The study was conducted in a laboratory setting and tested the compounds’ abilities to inhibit cell proliferation, induce cell death, and penetrate equine skin.

Research Context and Purpose

  • Equine sarcoid (ES) and equine malignant melanoma (EMM) are the most common skin cancers in horses. Current treatment options for these tumors are limited and present challenges, thus necessitating the exploration of more feasible solutions.
  • The study aimed to develop a suitable topical treatment for ES and EMM. For this purpose, NVX-207 and betulinyl-bis-sulfamate were chosen for evaluation. These two substances are derivatives of betulin and betulinic acid, respectively, which occur naturally.
  • The research assessed the compounds’ abilities to affect cell proliferation, to cause cell death (cytotoxicity), and to induce programmed cell death (apoptosis) in ES cells, EMM cells, and equine dermal fibroblasts in an in vitro setting.

Methodology and Results

  • The research utilized different assays to measure the effects of the compounds on cell proliferation, cytotoxicity, and apoptosis. Findings showed that both NVX-207 and betulinyl-bis-sulfamate significantly inhibited the proliferation and metabolism of ES cells, EMM cells, and fibroblasts in a time- and dose-dependent manner.
  • NVX-207 was found to be more effective at inhibiting cancer cells compared to betulinyl-bis-sulfamate.
  • Both compounds caused changes to cell membranes and DNA fragmentation, an indication that they induce apoptosis as a primary mode of action.
  • Moreover, necrotic cells, which are cells that have died from injury or disease, accounted for less than 2% of all cells after 48 hours of treatment with NVX-207, suggesting minimal collateral damage.
  • The research also examined the potential skin penetration and permeation of NVX-207 using Franz-type diffusion cells and HPLC analysis. It was found that NVX-207 penetrated the different skin layers more than necessary, based on the calculated half-maximal inhibitory concentrations.

Implications

  • While the in vitro data shows promising potential for NVX-207 as a topical treatment for ES and EMM, these results are not immediately applicable to a clinical scenario. Further in vivo research is needed to assess the actual anticancer effects of NVX-207 when applied directly on ES and EMM in horses.
  • If successful, this research may pave the way for more effective, easy-to-use topical treatments for equine skin cancer, improving the quality of life of affected equines and making the work of veterinarians easier.

Cite This Article

APA
Weber LA, Funtan A, Paschke R, Delarocque J, Kalbitz J, Meißner J, Feige K, Kietzmann M, Cavalleri JV. (2020). In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer. PLoS One, 15(11), e0241448. https://doi.org/10.1371/journal.pone.0241448

Publication

PloS one
ISSN: 1932-6203
NlmUniqueID: 101285081
Country: United States
Language: English
Volume: 15
Issue: 11
Pages: e0241448
PII: e0241448

Researcher Affiliations

Weber, Lisa Annabel
  • Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Funtan, Anne
  • Biozentrum, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Paschke, Reinhard
  • Biozentrum, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Delarocque, Julien
  • Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Kalbitz, Jutta
  • BioSolutions Halle GmbH, Halle (Saale), Germany.
Meißner, Jessica
  • Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Feige, Karsten
  • Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Kietzmann, Manfred
  • Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Cavalleri, Jessika-Maximiliane V
  • Equine Internal Medicine, University Equine Clinic, University of Veterinary Medicine Vienna, Vienna, Austria.

MeSH Terms

  • Administration, Topical
  • Animals
  • Apoptosis / drug effects
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Dermis / pathology
  • Diffusion
  • Fibroblasts / drug effects
  • Fibroblasts / pathology
  • Horse Diseases / drug therapy
  • Horses
  • Inhibitory Concentration 50
  • Propanolamines / pharmacology
  • Propanolamines / therapeutic use
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / veterinary
  • Sulfonic Acids / pharmacology
  • Sulfonic Acids / therapeutic use
  • Triterpenes / administration & dosage
  • Triterpenes / pharmacology
  • Triterpenes / therapeutic use

Conflict of Interest Statement

The authors declare that no competing interests exist. The affiliation "BioSolutions Halle GmbH” of Dr. Jutta Kalbitz does not alter our adherence to PLOS ONE policies on sharing data and materials. As described in the Funding Statement, BioSolutions Halle GmbH is not a commercial funder, but an equal partner in the TopiDrugHorse project.

References

This article includes 88 references
  1. Scott DW, Miller WH. Equine dermatology. 2nd ed Maryland Heights: Elsevier Saunders; 2011.
  2. Scott D, Miller W. Equine dermatology I. S. Louis; 2003.
  3. Valentine BA. Survey of equine cutaneous neoplasia in the Pacific Northwest.. J Vet Diagn Invest 2006 Jan;18(1):123-6.
    doi: 10.1177/104063870601800121pubmed: 16566271google scholar: lookup
  4. Goodrich L, Gerber H, Marti E, Antczak DF. Equine sarcoids.. Vet Clin North Am Equine Pract 1998 Dec;14(3):607-23, vii.
    doi: 10.1016/S0749-0739(17)30189-xpubmed: 9891727google scholar: lookup
  5. Pascoe RR, Summers PM. Clinical survey of tumours and tumour-like lesions in horses in south east Queensland.. Equine Vet J 1981 Oct;13(4):235-9.
    doi: 10.1111/j.2042-3306.1981.tb03504.xpubmed: 6459231google scholar: lookup
  6. Baker JR, Leyland A. Histological survey of tumours of the horse, with particular reference to those ofthe skin.. Vet Rec 1975 May 10;96(19):419-22.
    doi: 10.1136/vr.96.19.419pubmed: 1173477google scholar: lookup
  7. Marti E, Lazary S, Antczak DF, Gerber H. Report of the first international workshop on equine sarcoid.. Equine Vet J 1993 Sep;25(5):397-407.
    doi: 10.1111/j.2042-3306.1993.tb02981.xpubmed: 8223371google scholar: lookup
  8. Chambers G, Ellsmore VA, O'Brien PM, Reid SWJ, Love S, Campo MS, Nasir L. Association of bovine papillomavirus with the equine sarcoid.. J Gen Virol 2003 May;84(Pt 5):1055-1062.
    doi: 10.1099/vir.0.18947-0pubmed: 12692268google scholar: lookup
  9. Yuan Z, Gault EA, Campo MS, Nasir L. Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts.. J Gen Virol 2011 Apr;92(Pt 4):773-83.
    doi: 10.1099/vir.0.028191-0pubmed: 21177927google scholar: lookup
  10. Martens A, De Moor A, Ducatelle R. PCR detection of bovine papilloma virus DNA in superficial swabs and scrapings from equine sarcoids.. Vet J 2001 May;161(3):280-6.
    doi: 10.1053/tvjl.2000.0524pubmed: 11352485google scholar: lookup
  11. Hainisch EK, Brandt S. Equine Sarcoid. Seventh Ed Elsevier Inc.; 2014.
    doi: 10.1016/B978-1-4557-4555-5.00099-6google scholar: lookup
  12. Knottenbelt DC. A suggested clinical classification for the equine sarcoid. Clin Tech Equine Pract 2005;4:278–295.
    doi: 10.1053/j.ctep.2005.10.008google scholar: lookup
  13. Staiger EA, Tseng CT, Miller D, Cassano JM, Nasir L, Garrick D, Brooks SA, Antczak DF. Host genetic influence on papillomavirus-induced tumors in the horse.. Int J Cancer 2016 Aug 15;139(4):784-92.
    doi: 10.1002/ijc.30120pubmed: 27037728google scholar: lookup
  14. Angelos J, Oppenheim Y, Rebhun W, Mohammed H, Antczak DF. Evaluation of breed as a risk factor for sarcoid and uveitis in horses.. Anim Genet 1988;19(4):417-25.
    doi: 10.1111/j.1365-2052.1988.tb00833.xpubmed: 3232865google scholar: lookup
  15. Knottenbelt DC. The Equine Sarcoid: Why Are There so Many Treatment Options?. Vet Clin North Am Equine Pract 2019 Aug;35(2):243-262.
    doi: 10.1016/j.cveq.2019.03.006pubmed: 31097356google scholar: lookup
  16. Stadler S, Kainzbauer C, Haralambus R, Brehm W, Hainisch E, Brandt S. Successful treatment of equine sarcoids by topical aciclovir application.. Vet Rec 2011 Feb 19;168(7):187.
    doi: 10.1136/vr.c5430pubmed: 21493530google scholar: lookup
  17. Haspeslagh M, Jordana Garcia M, Vlaminck LEM, Martens AM. Topical use of 5% acyclovir cream for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-controlled study.. BMC Vet Res 2017 Oct 6;13(1):296.
    doi: 10.1186/s12917-017-1215-0pmc: PMC6389201pubmed: 28985733google scholar: lookup
  18. Nogueira SA, Torres SM, Malone ED, Diaz SF, Jessen C, Gilbert S. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study.. Vet Dermatol 2006 Aug;17(4):259-65.
    doi: 10.1111/j.1365-3164.2006.00526.xpubmed: 16827669google scholar: lookup
  19. Wilford S, Woodward E, Dunkel B. Owners' perception of the efficacy of Newmarket bloodroot ointment in treating equine sarcoids.. Can Vet J 2014 Jul;55(7):683-6.
    pmc: PMC4060914pubmed: 24982522
  20. Taylor S, Haldorson G. A review of equine sarcoid. Equine Vet Educ 2013;25:210–216.
    doi: 10.1111/j.2042-3292.2012.00411.xgoogle scholar: lookup
  21. Teixeira RB, Rendahl AK, Anderson SM, Mickelson JR, Sigler D, Buchanan BR, Coleman RJ, McCue ME. Coat color genotypes and risk and severity of melanoma in gray quarter horses.. J Vet Intern Med 2013 Sep-Oct;27(5):1201-8.
    doi: 10.1111/jvim.12133pubmed: 23875712google scholar: lookup
  22. Seltenhammer MH, Simhofer H, Scherzer S, Zechner R, Curik I, Sölkner J, Brandt SM, Jansen B, Pehamberger H, Eisenmenger E. Equine melanoma in a population of 296 grey Lipizzaner horses.. Equine Vet J 2003 Mar;35(2):153-7.
    doi: 10.2746/042516403776114234pubmed: 12638791google scholar: lookup
  23. Fleury C, Bérard F, Balme B, Thomas L. The study of cutaneous melanomas in Camargue-type gray-skinned horses (1): clinical-pathological characterization.. Pigment Cell Res 2000 Feb;13(1):39-46.
    doi: 10.1034/j.1600-0749.2000.130108.xpubmed: 10761995google scholar: lookup
  24. McFadyean J. Equine melanomatosis. J Comp Pathol Ther 1933;46:186–204.
    doi: 10.1016/S0368-1742(33)80025-7google scholar: lookup
  25. Rodriguez M, Garcia-Barona V, Pena L, Castano M, Rodriguez A. Grey Horse Melanotic Condition. J Equine Vet Sci 1997;17:677–81.
  26. Valentine BA. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991).. J Vet Intern Med 1995 Sep-Oct;9(5):291-7.
    doi: 10.1111/j.1939-1676.1995.tb01087.xpubmed: 8531173google scholar: lookup
  27. Rosengren Pielberg G, Golovko A, Sundström E, Curik I, Lennartsson J, Seltenhammer MH, Druml T, Binns M, Fitzsimmons C, Lindgren G, Sandberg K, Baumung R, Vetterlein M, Strömberg S, Grabherr M, Wade C, Lindblad-Toh K, Pontén F, Heldin CH, Sölkner J, Andersson L. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse.. Nat Genet 2008 Aug;40(8):1004-9.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  28. Sundström E, Komisarczuk AZ, Jiang L, Golovko A, Navratilova P, Rinkwitz S, Becker TS, Andersson L. Identification of a melanocyte-specific, microphthalmia-associated transcription factor-dependent regulatory element in the intronic duplication causing hair greying and melanoma in horses.. Pigment Cell Melanoma Res 2012 Jan;25(1):28-36.
    doi: 10.1111/j.1755-148X.2011.00902.xpubmed: 21883983google scholar: lookup
  29. MacGillivray KC, Sweeney RW, Del Piero F. Metastatic melanoma in horses.. J Vet Intern Med 2002 Jul-Aug;16(4):452-6.
    pubmed: 12141308doi: 10.1892/0891-6640(2002)016<0452:mmih>2.3.co;2google scholar: lookup
  30. Scott D. Neoplastic Diseases. In: Pedersen D, editor. Large animal dermatology. Philadelphia, USA: W.B. Saunders Company; 1988, p. 448–452.
  31. Moore JS, Shaw C, Shaw E, Buechner-Maxwell V, Scarratt WK, Crisman M. Melanoma in horses: current perspectives. Equine Vet Educ 2013;25:144–151.
    doi: 10.1111/j.2042-3292.2011.00368.xgoogle scholar: lookup
  32. Müller J, Feige K, Wunderlin P, Hödl A, Meli ML, Seltenhammer M, Grest P, Nicolson L, Schelling C, Heinzerling LM. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses.. J Immunother 2011 Jan;34(1):58-64.
    doi: 10.1097/CJI.0b013e3181fe1997pubmed: 21150713google scholar: lookup
  33. Phillips JC, Lembcke LM. Equine melanocytic tumors.. Vet Clin North Am Equine Pract 2013 Dec;29(3):673-87.
    doi: 10.1016/j.cveq.2013.08.008pubmed: 24267683google scholar: lookup
  34. Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.. BMC Vet Res 2015 Jun 11;11:132.
    doi: 10.1186/s12917-015-0422-9pmc: PMC4464139pubmed: 26063232google scholar: lookup
  35. Laus F, Cerquetella M, Paggi E, Ippedico G, Argentieri M, Castellano G. Evaluation of cimetidine as a therapy for dermal melanomatosis in grey horse. Isr J Vet Med 2010;65:47–52.
  36. Goetz TE, Ogilvie GK, Keegan KG, Johnson PJ. Cimetidine for treatment of melanomas in three horses.. J Am Vet Med Assoc 1990 Feb 1;196(3):449-52.
    pubmed: 2298676
  37. Bradley WM, Schilpp D, Khatibzadeh SM. Electronic brachytherapy used for the successful treatment of three different types of equine tumours. Equine Vet Educ 2017;29:293–298.
    doi: 10.1111/eve.12420google scholar: lookup
  38. Groom LM, Sullins KE. Surgical excision of large melanocytic tumours in grey horses: 38 cases (2001–2013). Equine Vet Educ 2018;30:438–443.
    doi: 10.1111/eve.12767google scholar: lookup
  39. Rowe EL, Sullins KE. Excision as treatment of dermal melanomatosis in horses: 11 cases (1994-2000).. J Am Vet Med Assoc 2004 Jul 1;225(1):94-6.
    doi: 10.2460/javma.2004.225.94pubmed: 15239480google scholar: lookup
  40. Théon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004).. J Am Vet Med Assoc 2007 May 15;230(10):1506-13.
    doi: 10.2460/javma.230.10.1506pubmed: 17504043google scholar: lookup
  41. Hewes CA, Sullins KE. Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).. J Am Vet Med Assoc 2006 Nov 15;229(10):1617-22.
    doi: 10.2460/javma.229.10.1617pubmed: 17107319google scholar: lookup
  42. Scacco L, Bolaffio C, Romano A, Fanciulli M, Baldi A, Spugnini EP. Adjuvant electrochemotherapy increases local control in a recurring equine anal melanoma. J Equine Vet Sci 2013;33:637–639.
    doi: 10.1016/j.jevs.2012.09.006google scholar: lookup
  43. Spugnini EP, D’Alterio GL, Dotsinsky I, Mudrov T, Dragonetti E, Murace R. Electrochemotherapy for the treatment of multiple melanomas in a horse. J Equine Vet Sci 2011;31:430–433.
    doi: 10.1016/j.jevs.2011.01.009google scholar: lookup
  44. Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs.. Mutat Res 1996 Aug 17;355(1-2):59-70.
    doi: 10.1016/0027-5107(96)00022-xpubmed: 8781577google scholar: lookup
  45. Weber LA, Meißner J, Delarocque J, Kalbitz J, Feige K, Kietzmann M, Michaelis A, Paschke R, Michael J, Pratscher B, Cavalleri JV. Betulinic acid shows anticancer activity against equine melanoma cells and permeates isolated equine skin in vitro.. BMC Vet Res 2020 Feb 5;16(1):44.
    doi: 10.1186/s12917-020-2262-5pmc: PMC7003431pubmed: 32024502google scholar: lookup
  46. Zalesińska MD, Borska S. Betulin and its derivatives–precursors of new drugs. World Sci News 2019;127:123–138.
  47. Yogeeswari P, Sriram D. Betulinic acid and its derivatives: a review on their biological properties.. Curr Med Chem 2005;12(6):657-66.
    doi: 10.2174/0929867053202214pubmed: 15790304google scholar: lookup
  48. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis.. Nat Med 1995 Oct;1(10):1046-51.
    doi: 10.1038/nm1095-1046pubmed: 7489361google scholar: lookup
  49. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME, Debatin KM. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors.. Cancer Res 1997 Nov 1;57(21):4956-64.
    pubmed: 9354463
  50. Ali-Seyed M, Jantan I, Vijayaraghavan K, Bukhari SN. Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy.. Chem Biol Drug Des 2016 Apr;87(4):517-36.
    doi: 10.1111/cbdd.12682pubmed: 26535952google scholar: lookup
  51. Ríos JL, Máñez S. New Pharmacological Opportunities for Betulinic Acid.. Planta Med 2018 Jan;84(1):8-19.
    doi: 10.1055/s-0043-123472pubmed: 29202513google scholar: lookup
  52. Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers.. Drug Discov Today 2009 Sep;14(17-18):885-90.
    doi: 10.1016/j.drudis.2009.05.015pubmed: 19520182google scholar: lookup
  53. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, Debatin KM. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid.. J Biol Chem 1998 Dec 18;273(51):33942-8.
    doi: 10.1074/jbc.273.51.33942pubmed: 9852046google scholar: lookup
  54. Mullauer FB, Kessler JH, Medema JP. Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion.. Apoptosis 2009 Feb;14(2):191-202.
    doi: 10.1007/s10495-008-0290-xpubmed: 19115109google scholar: lookup
  55. Raghuvar Gopal DV, Narkar AA, Badrinath Y, Mishra KP, Joshi DS. Protection of Ewing's sarcoma family tumor (ESFT) cell line SK-N-MC from betulinic acid induced apoptosis by alpha-DL-tocopherol.. Toxicol Lett 2004 Nov 2;153(2):201-12.
    doi: 10.1016/j.toxlet.2004.03.027pubmed: 15451550google scholar: lookup
  56. Tan Y, Yu R, Pezzuto JM. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation.. Clin Cancer Res 2003 Jul;9(7):2866-75.
    pubmed: 12855667
  57. Chowdhury AR, Mandal S, Mittra B, Sharma S, Mukhopadhyay S, Majumder HK. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives.. Med Sci Monit 2002 Jul;8(7):BR254-65.
    pubmed: 12118187
  58. Gheorgheosu D, Jung M, Ören B, Schmid T, Dehelean C, Muntean D, Brüne B. Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma.. Biol Chem 2013 Jun;394(6):773-81.
    doi: 10.1515/hsz-2013-0106pubmed: 23399635google scholar: lookup
  59. Karna E, Szoka L, Palka JA. Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells.. Mol Cell Biochem 2010 Jul;340(1-2):15-20.
    doi: 10.1007/s11010-010-0395-8pubmed: 20174965google scholar: lookup
  60. Ren W, Qin L, Xu Y, Cheng N. Inhibition of betulinic acid to growth and angiogenesis of human colorectal cancer cell in nude mice. Chinese-German J Clin Oncol 2010;9:153–157.
    doi: 10.1007/s10330-010-0002-1google scholar: lookup
  61. Gauthier C, Legault J, Lebrun M, Dufour P, Pichette A. Glycosidation of lupane-type triterpenoids as potent in vitro cytotoxic agents.. Bioorg Med Chem 2006 Oct 1;14(19):6713-25.
    doi: 10.1016/j.bmc.2006.05.075pubmed: 16787747google scholar: lookup
  62. Csuk R. Betulinic acid and its derivatives: a patent review (2008-2013).. Expert Opin Ther Pat 2014 Aug;24(8):913-23.
    doi: 10.1517/13543776.2014.927441pubmed: 24909232google scholar: lookup
  63. Winum JY, Pastorekova S, Jakubickova L, Montero JL, Scozzafava A, Pastorek J, Vullo D, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.. Bioorg Med Chem Lett 2005 Feb 1;15(3):579-84.
    doi: 10.1016/j.bmcl.2004.11.058pubmed: 15664816google scholar: lookup
  64. Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound.. Eur J Clin Invest 2009 May;39(5):384-94.
    doi: 10.1111/j.1365-2362.2009.02105.xpubmed: 19309323google scholar: lookup
  65. Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R, Vordermark D. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization.. Int J Mol Sci 2014 Oct 30;15(11):19777-90.
    doi: 10.3390/ijms151119777pmc: PMC4264138pubmed: 25361208google scholar: lookup
  66. Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JM, Paschke R. In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and in vivo safety assessment of the compound NVX-207 in two horses.. Chem Biol Interact 2016 Feb 25;246:20-9.
    doi: 10.1016/j.cbi.2016.01.002pubmed: 26772157google scholar: lookup
  67. Weber LA, Puff C, Kalbitz J, Kietzmann M, Feige K, Bosse K, Rohn K, Cavalleri JV. Concentration profiles and safety of topically applied betulinic acid and NVX-207 in eight healthy horses-A randomized, blinded, placebo-controlled, crossover pilot study.. J Vet Pharmacol Ther 2021 Jan;44(1):47-57.
    doi: 10.1111/jvp.12903pubmed: 32845519google scholar: lookup
  68. Team RDC, R Development Core Team R. R: A Language and Environment for Statistical Computing. 2008.
    doi: 10.1007/978-3-540-74686-7google scholar: lookup
  69. Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. J R Stat Soc Ser B Stat Methodol 2011;73:3–36.
    doi: 10.1111/j.1467-9868.2010.00749.xgoogle scholar: lookup
  70. Mourdjeva M, Kyurkchiev D, Mandinova A, Altankova I, Kehayov I, Kyurkchiev S. Dynamics of membrane translocation of phosphatidylserine during apoptosis detected by a monoclonal antibody.. Apoptosis 2005 Jan;10(1):209-17.
    doi: 10.1007/s10495-005-6076-5pubmed: 15711937google scholar: lookup
  71. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.. J Immunol 1992 Apr 1;148(7):2207-16.
    pubmed: 1545126
  72. Kommera H, Kaluderović GN, Bette M, Kalbitz J, Fuchs P, Fulda S, Mier W, Paschke R. In vitro anticancer studies of alpha- and beta-D-glucopyranose betulin anomers.. Chem Biol Interact 2010 Apr 29;185(2):128-36.
    doi: 10.1016/j.cbi.2010.02.038pubmed: 20193672google scholar: lookup
  73. Kommera H, Kaluderović GN, Kalbitz J, Dräger B, Paschke R. Small structural changes of pentacyclic lupane type triterpenoid derivatives lead to significant differences in their anticancer properties.. Eur J Med Chem 2010 Aug;45(8):3346-53.
    doi: 10.1016/j.ejmech.2010.04.018pubmed: 20472329google scholar: lookup
  74. Ferreira D, Adega F, Chaves R. The importance of cancer cell lines as in vitro models in cancer methylome analysis and anticancer drugs testing Oncogenomics cancer proteomics—Nov. approaches Biomarkers Discov. Ther. Targets Cancer. InTech vol. 3, 2013, p. 139–166.
    doi: 10.5772/53110google scholar: lookup
  75. Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, Ibbs M, Bliźniak R, Łuczewski Ł, Lamperska K. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures.. Arch Med Sci 2018 Jun;14(4):910-919.
    doi: 10.5114/aoms.2016.63743pmc: PMC6040128pubmed: 30002710google scholar: lookup
  76. van Staveren WC, Solís DY, Hébrant A, Detours V, Dumont JE, Maenhaut C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells?. Biochim Biophys Acta 2009 Apr;1795(2):92-103.
    doi: 10.1016/j.bbcan.2008.12.004pubmed: 19167460google scholar: lookup
  77. Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.. Expert Opin Investig Drugs 2018 Dec;27(12):963-970.
    doi: 10.1080/13543784.2018.1548608pubmed: 30426805google scholar: lookup
  78. Federici C, Lugini L, Marino ML, Carta F, Iessi E, Azzarito T, Supuran CT, Fais S. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.. J Enzyme Inhib Med Chem 2016;31(sup1):119-125.
    doi: 10.1080/14756366.2016.1177525pubmed: 27142956google scholar: lookup
  79. Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, Niebauer GW. Comparative histopathology of grey-horse-melanoma and human malignant melanoma.. Pigment Cell Res 2004 Dec;17(6):674-81.
    doi: 10.1111/j.1600-0749.2004.00192.xpubmed: 15541026google scholar: lookup
  80. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms.. Vet Pathol 2002 Nov;39(6):651-78.
    doi: 10.1354/vp.39-6-651pubmed: 12450197google scholar: lookup
  81. Tarwid J, Fretz P, Clark E. Equine sarcoids: a study with emphasis on pathologic diagnosis. Compend Contin Educ Pract Vet 1985;7:293–301.
  82. Martens A, De Moor A, Demeulemeester J, Ducatelle R. Histopathological characteristics of five clinical types of equine sarcoid.. Res Vet Sci 2000 Dec;69(3):295-300.
    doi: 10.1053/rvsc.2000.0432pubmed: 11124103google scholar: lookup
  83. Stahl J, Kietzmann M. The effects of chemical and physical penetration enhancers on the percutaneous permeation of lidocaine through equine skin.. BMC Vet Res 2014 Jun 20;10:138.
    doi: 10.1186/1746-6148-10-138pmc: PMC4078091pubmed: 24950611google scholar: lookup
  84. Luís A, Ruela M, Perissinato AG, Esselin M, Lino DS. Evaluation of skin absorption of drugs from topical and transdermal formulations. Brazilian J Pharm Sci 2016;52:527–544.
    doi: 10.1590/S1984-82502016000300018google scholar: lookup
  85. Guy RH, Hadgraft J. Prediction of drug disposition kinetics in skin and plasma following topical administration.. J Pharm Sci 1984 Jul;73(7):883-7.
    doi: 10.1002/jps.2600730706pubmed: 6470948google scholar: lookup
  86. Prausnitz MR, Elias PM, Franz TJ, Schmuth M, Tsai J-C, Menon GK. Skin barrier and transdermal drug delivery. Med Ther 2012;5:2065–2073.
  87. Haspeslagh M, Taevernier L, Maes AA, Vlaminck LE, De Spiegeleer B, Croubels SM, Martens AM. Topical distribution of acyclovir in normal equine skin and equine sarcoids: An in vitro study.. Res Vet Sci 2016 Jun;106:107-11.
    doi: 10.1016/j.rvsc.2016.03.021pubmed: 27234546google scholar: lookup
  88. Mills PC, Cross SE. Regional differences in the in vitro penetration of hydrocortisone through equine skin.. J Vet Pharmacol Ther 2006 Feb;29(1):25-30.
    doi: 10.1016/j.rvsc.2006.07.015pubmed: 16420298google scholar: lookup

Citations

This article has been cited 3 times.
  1. Gielecińska A, Kciuk M, Mujwar S, Celik I, Kołat D, Kałuzińska-Kołat Ż, Kontek R. Substances of Natural Origin in Medicine: Plants vs. Cancer.. Cells 2023 Mar 23;12(7).
    doi: 10.3390/cells12070986pubmed: 37048059google scholar: lookup
  2. Yi Z, Gao Y, Yu F, Zhu Y, Liu H, Li J, Murua Escobar H. Interventions for treatment of cutaneous melanoma in horses: a structured literature review.. Vet Res Commun 2023 Jun;47(2):347-360.
    doi: 10.1007/s11259-022-10023-8pubmed: 36329228google scholar: lookup
  3. Weber LA, Delarocque J, Feige K, Kietzmann M, Kalbitz J, Meißner J, Paschke R, Cavalleri JV. Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses.. Animals (Basel) 2021 Nov 13;11(11).
    doi: 10.3390/ani11113250pubmed: 34827981google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.